Dataset from A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myocardial Infarction

This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).

本研究旨在评估在ASA治疗基础上，每日两次给药的新型药物替格瑞洛（ticagrelor）是否可降低心血管事件的发生频率，此类事件包括心脏病致死、心肌梗死或脑卒中。